Vertex gets early OK for new drug
Kalydeco to treat certain patients with cystic fibrosis
Acting three months before its scheduled decision date, the Food and Drug Administration yesterday approved a drug developed by Vertex Pharmaceuticals Inc. to treat some patients suffering from cystic fibrosis, a rare and often fatal genetic disease. The drug, called Kalydeco, is the second therapy from the Cambridge company to receive the FDA’s blessing in the past eight months. Its first drug, Incivek, was approved in May to combat the hepatitis C virus.